Supernus Pharmaceuticals Reports Strong Q1 2026 Financial Results
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company specializing in products for central nervous system (CNS) diseases, announced its financial results for the first quarter of 2026 on May 5, 2026. The company showcased significant growth, driven by its key products, with notable revenue increases across its portfolio.
1. Impressive Revenue Growth
Supernus Pharmaceuticals reported a 56% year-over-year increase in combined revenues from its growth products, reflecting a robust start to the year. Jack Khattar, President and CEO, expressed optimism about the company's trajectory, stating, "We have positive momentum across our business, and I look forward to continued strong growth and execution of our key products throughout the year."
Key Revenue Highlights
- ONAPGO: The net product sales reached $8.4 million following the resumption of new patient initiations in February 2026. Since its launch in April 2025, approximately 2,200 enrollment forms have been submitted by over 645 prescribers. The company anticipates a regulatory submission for a second supplier to the FDA in Q3 2026, with potential approval by mid-2027.
- ZURZUVAE: Collaboration revenue from ZURZUVAE amounted to $27.6 million, representing a 100% increase in first-quarter U.S. sales compared to 2025. The number of prescriptions surged by 82% year-over-year.
- Qelbree: Sales rose 20% to $77.9 million, with total prescriptions reaching 254,824, an increase of 19% from the previous year.
- GOCOVRI: Revenues increased 15% to $35.2 million, with a 7% rise in total prescriptions compared to the same quarter last year.
Total Revenue Overview
The company reported total revenues of $207.7 million for the first quarter, a 39% increase from $149.8 million in 2025. This growth is attributed to both product sales and collaboration revenues.
2. Financial Performance Metrics
Supernus' financial highlights included:
- Adjusted Operating Earnings: The adjusted operating earnings (non-GAAP) were $28.7 million, compared to $25.9 million in Q1 2025.
- Net Loss: The company reported a net loss of $2.3 million, or $0.04 per diluted share, significantly improved from a net loss of $11.8 million (or $0.21 per diluted share) in the prior year.
- Operating Loss: The operating loss for Q1 2026 was $8.3 million, an improvement from a loss of $10.3 million in Q1 2025, largely due to higher revenues and lower contingent consideration losses.
- Cash Position: As of March 31, 2026, cash, cash equivalents, and current marketable securities totaled approximately $384.2 million, up from $308.7 million at the end of 2025.
3. Product Pipeline Progress
Supernus is actively advancing its product pipeline with several promising candidates:
- SPN-817: A Phase 2b study is ongoing for this novel AChE inhibitor for epilepsy, with a target enrollment of 258 adults with treatment-resistant focal seizures.
- SPN-820: This novel molecule for depression is in a Phase 2b trial involving approximately 200 adults with major depressive disorder (MDD), focusing on its safety and rapid onset of improvement in depressive symptoms.
- SPN-443: This novel stimulant for ADHD is expected to enter a Phase 1 study in adult healthy volunteers in the second half of 2026.
4. Full-Year 2026 Guidance
Supernus reiterated its full-year financial guidance, projecting total revenues between $840 million and $870 million, with ONAPGO net sales estimated at $45 million to $70 million. The combined R&D and SG&A expenses are expected to be between $620 million and $650 million.
5. Conclusion
The Q1 2026 financial results reflect Supernus Pharmaceuticals' strong operational performance and potential for future growth. With a solid cash position, increasing revenues from key products, and a promising pipeline, the company is well-positioned to continue its trajectory in the biopharmaceutical sector focused on CNS disorders. Investors will be keen to follow the company’s progress as they execute their growth strategy throughout the year.
